Arbutus Biopharma Corporation Statistics
Share Statistics
Arbutus Biopharma Corporation has 189.49M shares outstanding. The number of shares has increased by 5.57% in one year.
| Shares Outstanding | 189.49M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.38% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 147.38M |
| Failed to Deliver (FTD) Shares | 8.83K |
| FTD / Avg. Volume | 1.02% |
Short Selling Information
The latest short interest is 5.97M, so 3.15% of the outstanding shares have been sold short.
| Short Interest | 5.97M |
| Short % of Shares Out | 3.15% |
| Short % of Float | 4.05% |
| Short Ratio (days to cover) | 7.03 |
Valuation Ratios
The PE ratio is -5.7 and the forward PE ratio is -10.71.
| PE Ratio | -5.7 |
| Forward PE | -10.71 |
| PS Ratio | 22.87 |
| Forward PS | 75.9 |
| PB Ratio | 3.91 |
| P/FCF Ratio | -4.77 |
| PEG Ratio | n/a |
Enterprise Valuation
Arbutus Biopharma Corporation has an Enterprise Value (EV) of 397.34M.
| EV / Earnings | -5.45 |
| EV / Sales | 21.9 |
| EV / EBITDA | -5.6 |
| EV / EBIT | -5.09 |
| EV / FCF | -4.57 |
Financial Position
The company has a current ratio of 5.87, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.87 |
| Quick Ratio | 5.87 |
| Debt / Equity | 0.07 |
| Total Debt / Capitalization | 6.15 |
| Cash Flow / Debt | -12.36 |
| Interest Coverage | -170.16 |
Financial Efficiency
Return on equity (ROE) is -0.69% and return on capital (ROIC) is -68.07%.
| Return on Equity (ROE) | -0.69% |
| Return on Assets (ROA) | -0.5% |
| Return on Capital (ROIC) | -68.07% |
| Revenue Per Employee | 248.51K |
| Profits Per Employee | -997.93K |
| Employee Count | 73 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 36.95% in the last 52 weeks. The beta is 1.92, so Arbutus Biopharma Corporation's price volatility has been higher than the market average.
| Beta | 1.92 |
| 52-Week Price Change | 36.95% |
| 50-Day Moving Average | 3.58 |
| 200-Day Moving Average | 3.47 |
| Relative Strength Index (RSI) | 50.72 |
| Average Volume (20 Days) | 863.36K |
Income Statement
In the last 12 months, Arbutus Biopharma Corporation had revenue of 18.14M and earned -72.85M in profits. Earnings per share was -0.44.
| Revenue | 18.14M |
| Gross Profit | -55.56M |
| Operating Income | -78.10M |
| Net Income | -72.85M |
| EBITDA | -70.99M |
| EBIT | -78.10M |
| Earnings Per Share (EPS) | -0.44 |
Balance Sheet
The company has 26.29M in cash and 8.72M in debt, giving a net cash position of 17.56M.
| Cash & Cash Equivalents | 26.29M |
| Total Debt | 8.72M |
| Net Cash | 17.56M |
| Retained Earnings | -1.28B |
| Total Assets | 140.44M |
| Working Capital | 113.85M |
Cash Flow
In the last 12 months, operating cash flow was -85.94M and capital expenditures -1.01M, giving a free cash flow of -86.94M.
| Operating Cash Flow | -85.94M |
| Capital Expenditures | -1.01M |
| Free Cash Flow | -86.94M |
| FCF Per Share | -0.52 |
Margins
Gross margin is -30.63K%, with operating and profit margins of -43.05K% and -40.16K%.
| Gross Margin | -30.63K% |
| Operating Margin | -43.05K% |
| Pretax Margin | -40.16K% |
| Profit Margin | -40.16K% |
| EBITDA Margin | -391.3% |
| EBIT Margin | -430.53% |
| FCF Margin | -479.27% |
Dividends & Yields
ABUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -12.9% |
| FCF Yield | -13.46% |
Analyst Forecast
The average price target for ABUS is $5, which is 46.6% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5 |
| Price Target Difference | 46.6% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Nov 4, 2010. It was a backward split with a ratio of 1:5.
| Last Split Date | Nov 4, 2010 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | -3.3 |
| Piotroski F-Score | 3 |